JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D.
Diabetes UK is a co-funder of AdDIT and the leading charitable funder of diabetes research in the UK. They invest around £7 million every year to bring about life-changing breakthroughs in care, treatment and prevention, ultimately bringing us closer to a cure.
The British Heart Foundation are the largest independent funder of cardiovascular research in the UK, turning your donations into discoveries. With your help, we invest £100m a year to find the next breakthrough against heart and circulatory diseases.
Additional support Provided by:
UK Medical Director – Dr Berkeley Philips
Provided the investigational medicinal products, Atorvastatin, Quinapril and matched Placebos.
AARDEX Ltd, Switzerland; Provided Electronic Pill Monitoring Caps.
Now trading as WestRock Switzerland Ltd
Canada received additional funding from:
Thank you to Catalent Pharma Solutions UK who helped us package and distribute all of the drugs through the trial.